Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

医学 乳腺癌 内科学 肿瘤科 临床试验 癌症 合并分析 荟萃分析
作者
Carsten Denkert,Fenja Seither,Andreas Schneeweiß,Theresa Link,Jens‐Uwe Blohmer,Marianne Just,Pauline Wimberger,Almuth Forberger,Hans Tesch,Christian Jackisch,Sabine Schmatloch,Mattea Reinisch,Erich Franz Solomayer,Wolfgang Schmitt,Claus Alexander Hanusch,Peter Andreas Fasching,Kristina Lübbe,Christine Solbach,Jens Huober,Kerstin Rhiem
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (8): 1151-1161 被引量:623
标识
DOI:10.1016/s1470-2045(21)00301-6
摘要

The development of anti-HER2 antibody-drug conjugates opens new therapeutic options for patients with breast cancer, including patients with low expression of HER2. To characterise this new breast cancer subtype, we have compared the clinical and molecular characteristics of HER2-low-positive and HER2-zero breast cancer, including response to neoadjuvant chemotherapy and prognosis.In this pooled analysis of individual patient data, we evaluated a cohort of 2310 patients with HER2-non-amplified primary breast cancer that were treated with neoadjuvant combination chemotherapy in four prospective neoadjuvant clinical trials (GeparSepto, NCT01583426; GeparOcto, NCT02125344; GeparX, NCT02682693; Gain-2 neoadjuvant, NCT01690702) between July 30, 2012, and March 20, 2019. Central HER2 testing was done prospectively before random assignment of participants in all trials. HER2-low-positive status was defined as immunohistochemistry (IHC) 1+ or IHC2+/in-situ hybridisation negative and HER2-zero was defined as IHC0, based on the American Society of Clinical Oncology/College of American Pathologists guidelines. Disease-free survival and overall survival data were available for 1694 patients (from all trials except GeparX) with a median follow-up of 46·6 months (IQR 35·0-52·3). Bivariable and multivariable logistic regression models and Cox-proportional hazards models were performed based on a predefined statistical analysis plan for analysis of the endpoints pathological complete response, disease-free survival, and overall survival.A total of 1098 (47·5%) of 2310 tumours were HER2-low-positive and 1212 (52·5%) were HER2-zero. 703 (64·0%) of 1098 patients with HER2-low-positive tumours were hormone receptor positive, compared with 445 (36·7%) of 1212 patients with HER2-zero tumours (p<0.0001). HER2-low-positive tumours had a significantly lower pathological complete response rate than HER2-zero tumours (321 [29·2%] of 1098 vs 473 [39·0%] of 1212, p=0·0002). Pathological complete response was also significantly lower in HER2-low-positive tumours versus HER2-zero tumours in the hormone receptor-positive subgroup (123 [17·5%] of 703 vs 105 [23·6%] of 445, p=0·024), but not in the hormone receptor-negative subgroup (198 [50·1%] of 395 vs 368 [48·0%] of 767, p=0·21). Patients with HER2-low-positive tumours had significantly longer survival than did patients with HER2-zero tumours (3-year disease-free survival: 83·4% [95% CI 80·5-85·9] vs 76·1% [72·9-79·0]; stratified log-rank test p=0·0084; 3-year overall survival: 91·6% [84·9-93·4] vs 85·8% [83·0-88·1]; stratified log-rank test p=0·0016). Survival differences were also seen in patients with hormone receptor-negative tumours (3-year disease-free survival: 84·5% [95% CI 79·5-88·3] vs 74·4% [70·2-78.0]; stratified log-rank test p=0·0076; 3-year overall survival: 90·2% [86·0-93·2] vs 84·3% [80·7-87·3], stratified log-rank test p=0·016), but not in patients with hormone receptor-positive tumours (3-year disease-free survival 82·8% [79·1-85·9] vs 79·3% [73·9-83·7]; stratified log-rank test p=0·39; 3-year overall survival 92·3% [89·6-94·4] vs 88·4% [83·8-91·8]; stratified log-rank test p=0·13).Our results show that HER2-low-positive tumours can be identified as new subgroup of breast cancer by standardised IHC, distinct from HER2-zero tumours. HER2-low-positive tumours have a specific biology and show differences in response to therapy and prognosis, which is particularly relevant in therapy-resistant, hormone receptor-negative tumours. Our results provide a basis for a better understanding of the biology of breast cancer subtypes and the refinement of future diagnostic and therapeutic strategies.German Cancer Aid (Deutsche Krebshilfe).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ty完成签到 ,获得积分10
1秒前
Ava的应助被Researcher采纳,获得10
1秒前
yoga完成签到,获得积分10
1秒前
笑笑完成签到,获得积分10
1秒前
SG完成签到,获得积分10
2秒前
2秒前
李李玲发布了新的文献求助10
2秒前
专注以筠完成签到,获得积分10
3秒前
煎饼狗子完成签到,获得积分10
3秒前
毛毛完成签到,获得积分10
4秒前
沉睡千年的蛆完成签到,获得积分10
4秒前
sukiii发布了新的文献求助10
4秒前
wl完成签到,获得积分10
4秒前
脆薯饼完成签到,获得积分10
5秒前
丰富的雅绿完成签到,获得积分10
5秒前
勇敢牛牛完成签到,获得积分10
5秒前
caozhi完成签到,获得积分10
6秒前
学习达人完成签到,获得积分10
6秒前
胡彦乱语的咖啡豆完成签到,获得积分10
7秒前
7秒前
阳光的柚子完成签到 ,获得积分10
8秒前
囍囍完成签到,获得积分20
8秒前
aaaddwdf完成签到,获得积分10
8秒前
roselin26完成签到,获得积分10
8秒前
8秒前
Nico_Ding完成签到,获得积分10
9秒前
9秒前
menghan完成签到,获得积分10
9秒前
实验小学五道杠大队长完成签到,获得积分10
10秒前
孙爽完成签到 ,获得积分10
10秒前
1b完成签到,获得积分10
10秒前
75986686发布了新的文献求助10
10秒前
亨利完成签到,获得积分10
10秒前
肘子派完成签到,获得积分10
11秒前
大气迎天完成签到,获得积分10
12秒前
陈瑞发布了新的文献求助10
13秒前
王贵康完成签到,获得积分10
13秒前
13秒前
piaopiao完成签到,获得积分10
13秒前
一一完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173463
求助须知:如何正确求助?哪些是违规求助? 9565690
关于积分的说明 21781315
捐赠科研通 7767647
什么是DOI,文献DOI怎么找? 3431597
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476808